SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding 
Federal Reserve Faces Subpoena Delay Amid Investigation Into Chair Jerome Powell 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
UnitedHealth Group (NYSE: UNH) is under investigation by the U.S. Department of Justice (DOJ) for potential criminal fraud related to its Medicare Advantage business, according to a report by the Wall Street Journal. The healthcare giant’s stock dropped 6.5% in after-hours trading, hitting a near five-year low amid the growing legal scrutiny.
The DOJ’s healthcare-fraud unit has reportedly been probing UnitedHealth since at least mid-2023. While the exact details of the criminal allegations remain unclear, the investigation focuses on whether the company engaged in fraudulent billing or reporting practices in its Medicare operations. This latest development adds to a series of legal challenges facing the insurer.
In addition to the criminal probe, UnitedHealth is also facing a civil investigation tied to Medicare billing practices and separate concerns over potential antitrust violations. The company’s business model, which heavily relies on federal healthcare programs, may come under further pressure as lawmakers consider cost-cutting measures, including efforts to reduce Medicare drug prices.
The mounting scrutiny has triggered leadership changes within the company. Earlier this week, UnitedHealth abruptly replaced CEO Andrew Witty with former CEO and current Chairman Stephen Hemsley. The leadership shakeup comes as the company’s stock has seen a sharp decline in 2025, reflecting investor concerns over its legal exposure and the potential for regulatory reforms.
The DOJ investigation could have significant implications not just for UnitedHealth, but for the broader Medicare Advantage sector, which has faced increased oversight in recent years. As more details emerge, analysts and investors will be closely watching for signs of financial or operational fallout.
